BACKGROUND: Early identification of children with familial hypercholesterolemia (FH) makes it possible to start lipid-lowering therapy at a young age in order to prevent cardiovascular disease. Numerous randomized, often placebo-controlled, studies have assessed the efficacy and safety of statins in children with FH. OBJECTIVE: The aim of this pragmatic observational study was to evaluate pravastatin treatment efficacy and tolerability for a long period of time, and to assess how these results translate in 'real-life' clinical practice. METHODS: We analyzed all medical files of young hypercholesterolemic patients referred to two specialized French centers. This population of 185 pravastatin-treated children with FH, with a mean baseline cholesterol level above 300 mg/dL, in most of whom genetic diagnosis was achieved, was followed-up for a mean duration of 2 years 2 months. The mean age for starting pravastatin was 11 years; in one of five children, treatment was started before the age of 8 years, mostly because of severe hypercholesterolemia or a family history of coronary heart disease. RESULTS: A 16.9-19.2% decrease in total cholesterol level (21-24% for low-density lipoprotein cholesterol) was observed. Growth and puberty were not affected by statin treatment. A review of the medical files showed that 13% of children had side effects, most of which were minor; four of these children had muscular symptoms possibly related to the treatment. This frequency is lower than that observed in adults, and comparable to other studies in children. CONCLUSIONS: In this large cohort of FH children, the efficacy and tolerability of pravastatin therapy in real-life conditions was demonstrated to be similar to that in randomized controlled studies.
BACKGROUND: Early identification of children with familial hypercholesterolemia (FH) makes it possible to start lipid-lowering therapy at a young age in order to prevent cardiovascular disease. Numerous randomized, often placebo-controlled, studies have assessed the efficacy and safety of statins in children with FH. OBJECTIVE: The aim of this pragmatic observational study was to evaluate pravastatin treatment efficacy and tolerability for a long period of time, and to assess how these results translate in 'real-life' clinical practice. METHODS: We analyzed all medical files of young hypercholesterolemicpatients referred to two specialized French centers. This population of 185 pravastatin-treated children with FH, with a mean baseline cholesterol level above 300 mg/dL, in most of whom genetic diagnosis was achieved, was followed-up for a mean duration of 2 years 2 months. The mean age for starting pravastatin was 11 years; in one of five children, treatment was started before the age of 8 years, mostly because of severe hypercholesterolemia or a family history of coronary heart disease. RESULTS: A 16.9-19.2% decrease in total cholesterol level (21-24% for low-density lipoprotein cholesterol) was observed. Growth and puberty were not affected by statin treatment. A review of the medical files showed that 13% of children had side effects, most of which were minor; four of these children had muscular symptoms possibly related to the treatment. This frequency is lower than that observed in adults, and comparable to other studies in children. CONCLUSIONS: In this large cohort of FHchildren, the efficacy and tolerability of pravastatin therapy in real-life conditions was demonstrated to be similar to that in randomized controlled studies.
Authors: Jessica Rodenburg; Maud N Vissers; Albert Wiegman; A S Paul van Trotsenburg; Anouk van der Graaf; Eric de Groot; Frits A Wijburg; John J P Kastelein; Barbara A Hutten Journal: Circulation Date: 2007-07-30 Impact factor: 29.690
Authors: Y Aggoun; D Bonnet; D Sidi; J P Girardet; E Brucker; M Polak; M E Safar; B I Levy Journal: Arterioscler Thromb Vasc Biol Date: 2000-09 Impact factor: 8.311
Authors: Albert Wiegman; Barbara A Hutten; Eric de Groot; Jessica Rodenburg; Henk D Bakker; Harry R Büller; Eric J G Sijbrands; John J P Kastelein Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: Saskia de Jongh; Marc R Lilien; Jos op't Roodt; Erik S G Stroes; Henk D Bakker; John J P Kastelein Journal: J Am Coll Cardiol Date: 2002-12-18 Impact factor: 24.094
Authors: Michael M Mendelson; Todd Regh; James Chan; Annette Baker; Heather Harker Ryan; Nicole Palumbo; Philip K Johnson; Suzanne Griggs; Meera Boghani; Nirav K Desai; Elizabeth Yellen; Lucy Buckley; Matthew W Gillman; Justin P Zachariah; Dionne Graham; Sarah D de Ferranti Journal: J Pediatr Date: 2016-08-31 Impact factor: 4.406
Authors: Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Serena Tonstad; Albert Wiegman; Euridiki Drogari; Uma Ramaswami Journal: Cochrane Database Syst Rev Date: 2017-07-07
Authors: Elizabeth Niedra; Nita Chahal; Cedric Manlhiot; Rae S M Yeung; Brian W McCrindle Journal: Pediatr Cardiol Date: 2013-07-18 Impact factor: 1.655
Authors: Ingrid C Gelissen; Huy Long Nguyen; Darren K Tiao; Rita Ayoub; Parisa Aslani; Rebekah Moles Journal: Paediatr Drugs Date: 2014-10 Impact factor: 3.022
Authors: Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Serena Tonstad; Albert Wiegman; Euridiki Drogari; Uma Ramaswami Journal: Cochrane Database Syst Rev Date: 2019-11-07
Authors: Nana O Wilson; Wesley Solomon; Leonard Anderson; John Patrickson; Sidney Pitts; Vincent Bond; Mingli Liu; Jonathan K Stiles Journal: PLoS One Date: 2013-04-05 Impact factor: 3.240